Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy
Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy
复制标题
与显着性网络相关的不同纹状体通路可预测利培酮单一疗法后精神分裂症的症状改善和弹性功能
DOI：
10.1016/j.schres.2019.11.017
复制
发表时间：
2020-01-01
影响因子：
4.5
通讯作者：
Chen, Huafu
中科院分区：
文献类型：
--
作者：
Han, Shaoqiang;Becker, Benjamin;Chen, Huafu
纹状体和显著网络（SN）之间的异常相互作用被认为是精神分裂症的病因学和治疗敏感性标志。然而，纹状体和显著性网络之间的静息状态功能连接（RSFC）所反映的内在动力学变化是否可以预测广泛使用的抗精神病药物治疗策略（利培酮，单药治疗）的治疗反应尚未系统地研究。为此，首次发作的精神分裂症患者（n = 41）在利培酮单药治疗前（基线）和8周后（n = 38）进行了无任务静息状态fMRI评估。检查纹状体子区域和核心显著性处理节点之间的内在连接，并与仔细匹配的健康对照（HC）进行比较，以确定疾病特异性和治疗预测性神经标志物。研究结果表明，在基线时，患者的腹侧和背侧纹状体-SN通路的连通性低下。重要的是，特别是背侧纹状体通路在基线时可以预测患者的阴性症状改善;而腹侧纹状体通路可以预测阳性症状改善。总之，结果表明，不同的纹状体-SN通路代表了利培酮作用的特定治疗成功标志物，这表明背侧与腹侧纹状体网络标志物的改变可能代表利培酮单药治疗后特定神经病学改善的脑标志物。(C)2019年爱思唯尔出版
Abnormal interactions between the striatum and salience network (SN) are considered as etiological and treatment-sensitive marker in schizophrenia. However, whether alterations in the intrinsic dynamics as reflected by resting-state functional connectivity (RSFC) between the striatum and salience network may predict treatment response to the widely used antipsychotic treatment strategies (risperidone, monotherapy) has not been examined systematically. To this end, treatment-naive first-episode schizophrenia patients (n = 41) underwent task-free resting-state fMRI assessment before (baseline) and after 8 weeks of risperidone monotherapy (n 38). Intrinsic connectivity between striatal sub-regions and core salience processing nodes were examined and compared to carefully matched healthy controls (HC) to determine disorder-specific and treatment-predictive neural markers. Findings demonstrate hypo-connectivity of both ventral and dorsal striatal-SN pathways in patients at baseline. Importantly, specifically the dorsal striatal pathway at baseline could predict negative symptoms improvement in patients; while ventral striatal pathways could predict positive symptoms improvement. Together, results indicate that distinct striatal-SN pathways represent specific treatment-success markers for the effects of risperidone, suggesting that alterations in dorsal versus ventral striatal network markers may represent brain-based markers for specific symptomatologic improvements following risperidone mono-therapy. (C) 2019 Published by Elsevier B.V.